fda approved glp-1 receptor agonists of GLP-1RAs for the treatment of type 2 diabetes. US Food GLP-1 Receptor Agonists: Small Molecule

Although GLP-1RAs can reduce body weight by 15%25% in controlled settings, real-world adherence is limited, and nearly 70% of patients experience weight regain after discontinuation, raising the risk of long-term pharmacological dependence ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications

By promoting angiogenesis, BPC-157 may address one of the fundamental limitations in soft tissue repair

concluded that IGF-1 LR3 may have been 2.5-fold more potent than IGF-I at improving weight gain and nitrogen retention

Who should avoid IV Drip Therapy or require medical clearance first

PlexusDx recommends discussing any dual-therapy plan with your prescribing provider before starting